TLX
Trans-Lux Corp.
NASDAQ · Healthcare · Biotechnology · AU
$10.74
+0.47%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- 129.80x
- P/E 2027E
- 187.46x
- P/E 2028E
- 44.14x
- P/S forward
- 33.72x
Trailing multiples
Trailing twelve months
- P/E TTM
- 111.26x
- PEG TTM
- —
- Price / book
- 7.42x
- Price / sales
- 3.98x
- Price / cash flow
- -272.30x
Enterprise value
- Enterprise value
- $4.0B
- EV / sales
- 4.34x
- EV / EBITDA
- 123.27x
- EV / EBIT
- -564.96x
- Market cap
- $3.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026